Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 9, 2019
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alphaBirong Zhang, James R Kiefer, Robert A Blake, et al.
Cell|February 21, 2017
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in CancerMichael R Burgess, Eugene Hwang, Rana Mroue, et al.
Journal of Medicinal Chemistry|October 16, 2012
Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitorsEmily J Hanan, Anne van Abbema, Kathy Barrett, et al.
Molecular Cancer Therapeutics|October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayJeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2013
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitorsMichael Siu, Richard Pastor, Wendy Liu, et al.
Leukemia|February 19, 2020
Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemiaAnica M Wandler, Benjamin J Huang, Jeffrey W Craig, et al.
Molecular Pharmaceutics|April 9, 2015
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancerSteven R Leong, Wei-Ching Liang, Yan Wu, et al.
Molecular Cancer Therapeutics|December 29, 2017
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Blood|March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
Bioorganic & Medicinal Chemistry Letters|June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinaseSteven T Staben, Michael Siu, Richard Goldsmith, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Bioorganic & Medicinal Chemistry Letters|February 9, 2019
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alphaBirong Zhang, James R Kiefer, Robert A Blake, et al.
Cell|February 21, 2017
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in CancerMichael R Burgess, Eugene Hwang, Rana Mroue, et al.
Journal of Medicinal Chemistry|October 16, 2012
Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitorsEmily J Hanan, Anne van Abbema, Kathy Barrett, et al.
Molecular Cancer Therapeutics|October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayJeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Bioorganic & Medicinal Chemistry Letters|July 23, 2013
2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitorsMichael Siu, Richard Pastor, Wendy Liu, et al.
Leukemia|February 19, 2020
Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemiaAnica M Wandler, Benjamin J Huang, Jeffrey W Craig, et al.
Molecular Pharmaceutics|April 9, 2015
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancerSteven R Leong, Wei-Ching Liang, Yan Wu, et al.
Molecular Cancer Therapeutics|December 29, 2017
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Blood|March 10, 2019
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D Zelenetz, Gilles Salles, Kylie D Mason, et al.
Bioorganic & Medicinal Chemistry Letters|June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinaseSteven T Staben, Michael Siu, Richard Goldsmith, et al.
Pageof 10